Meningitis outbreak shows why we need regulation
There are almost no laws governing the pharmaceutical process at the center of the meningitis oubreak
Topics: FDA, Disease, meningitis, Politics News
Vials of the injectable steroid product made by New England Compounding Center implicated in a fungal meningitis outbreak (Credit: AP/Minnesota Department of Health)If the Democrats needed an opportunity to show voters what a deregulated market really looks like, the New England Compounding Center, the company responsible for the current meningitis outbreak, has served one up.
According to the Wall Street Journal, the Framingham, Mass., center made as many as “17,676 potentially tainted steroid injections, which were then shipped to 75 clinics in 23 states.” So far 14 people have died and 170 have fallen ill from the contaminated shots. The questions on everybody’s mind now are: How could this happen? And where was the Food and Drug Administration, the federal agency that’s supposed to oversee the pharmaceutical industry?
How could it happen? Simple: There are almost no laws regulating pharmaceutical compounding, the process of making made-to-order prescriptions tailored to the unique needs of individual clients. This process used to take place on a small scale. But in the past 20 years, changes in the pharmaceuticals market allowed compounding to explode into a new industry of below-the-radar, unregulated mass drug production.
The government has been aware of the health risks posed by compounding for more than a decade. In 1997, the Food and Drug Administration Modernization Act (FDAMA) put significant restraints on the ways pharmacists could compound drugs. But the Supreme Court in 2002 struck down the part of the law that regulated compounding, finding that prohibiting the promotion and advertisement of compounded products unconstitutionally restrained free speech. No federal legislation has been enacted since then to take the section’s place. Instead, each state has to set its own regulations for governing the country’s approximately 3,000 compounding pharmacies, which collectively pull in about $9 billion of annual revenue.
This kind of state-by-state regulatory framework, which incidentally mirrors the Romney/Ryan proposal for the country’s oil and gas industries, has brought us a shadowy pharmaceutical underworld with almost zero federal oversight. Despite a 2002 FDA study that found 34 percent of compounded drugs failed basic tests and more than 200 known adverse compounding-related events between 1993 and 2000, there is very little the FDA can do to restrain these companies from producing and selling these dangerous drugs, which are used to fill more than 30 million prescriptions every year.
Deena Shanker is a writer living in New York City. You can follow her on Twitter @deenashanker. More Deena Shanker.








Comments
0 Comments